Lung Microbiome and Inflammation in Early COPD

Recruiting now

Conditions studied: Chronic Obstuctive Pulmonary Disease

In brief

This is a cross sectional case controlled study to assess lung microbiome and inflammation in smokers with and without Chronic Obstructive Pulmonary Disease (COPD). Investigators will look at active bacterial metabolic pathways in the lower airways using metagenomic and metabolomic approaches an assess relationships among microbiome, metagenome, metabolome and host immune responses in COPD and controls. Investigators believe COPD cases will have higher prevalence of pneumotype supraglottic predominant taxa (SPT) than matched controls.

Key facts

Study ID

NCT02777879

Run by

NYU Langone Health

People needed

230

Starts

2014-05-01

Expected to finish

2030-08-01

Last updated by the study team

2026-01-28

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Case definition: Smokers (>20 pack-year) with airflow obstruction (FEV1/FVC<70) and FEV1>50% predicted (early COPD GOLD 1 or 2)
• Control definition: Smokers with normal spirometry will serve as controls.

You may not qualify if…

• FEV1 < 50% NOT 70
• Significant cardiovascular disease defined as abnormal EKG, known or suspected coronary artery disease or congestive heart failure.
• Diabetes mellitus
• Significant liver or renal disease
• Severe coagulopathy (INR > 1.4, PTT > 40 seconds and platelet count < 150x103 cells).
• Pregnancy
• ETOH use of more than >6 beers or >4 mixed drinks daily
• Lack of capacity to provide informed consent.
• Antibiotic use within the prior 2months

Where it is running

• New York University School of Medicine — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.